Inhibiting the mitochondrial pyruvate carrier does not ameliorate synucleinopathy in the absence of inflammation or metabolic deficits
Epidemiological studies suggest a link between type-2 diabetes and Parkinson’s disease (PD) risk. Treatment of type-2 diabetes with insulin sensitizing drugs lowers the risk of PD. We previously showed that the insulin sensitizing drug, MSDC-0160, ameliorates pathogenesis in some animal models of PD...
Main Authors: | Wouter Peelaerts, Liza Bergkvist, Sonia George, Michaela Johnson, Lindsay Meyerdirk, Emily Schulz, Jennifer A. Steiner, Zachary Madaj, Jiyan Ma, Katelyn Becker, K. Peter R. Nilsson, Jerry R. Colca, Patrik Brundin |
---|---|
Format: | Article |
Language: | English |
Published: |
University of Münster / Open Journals System
2020-11-01
|
Series: | Free Neuropathology |
Subjects: | |
Online Access: | https://www.uni-muenster.de/Ejournals/index.php/fnp/article/view/3049 |
Similar Items
-
Reduced Cytosolic Calcium as an Early Decisive Cellular State in Parkinson’s Disease and Synucleinopathies
by: Cristine Betzer, et al.
Published: (2018-11-01) -
Phytochemicals as Regulators of Genes Involved in Synucleinopathies
by: Andrei Surguchov, et al.
Published: (2021-04-01) -
A New Rise of Non-Human Primate Models of Synucleinopathies
by: Margaux Teil, et al.
Published: (2021-03-01) -
Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal α-synuclein preformed fibrils
by: Joseph R. Patterson, et al.
Published: (2019-10-01) -
Enteric synucleinopathy: real entity or only a trendy concept?
by: Adrien de Guilhem de Lataillade, et al.
Published: (2020-08-01)